PT-141 Research: Bremelanotide, Melanocortin Receptors, and CNS Pathway Studies

What Is PT-141?

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II by removal of the C-terminal amide. CAS 189691-06-3, molecular weight 1,025.2 Da. As a melanocortin receptor agonist, PT-141 demonstrates binding affinity across multiple receptor subtypes, MC1R, MC3R, MC4R, and MC5R, with primary research interest focused on MC4R given its central role in energy homeostasis and CNS regulatory pathways.

The melanocortin system is a broadly distributed neuroendocrine signaling network originating from pro-opiomelanocortin (POMC)-expressing neurons in the arcuate nucleus of the hypothalamus. POMC-derived peptides including alpha-MSH serve as endogenous ligands for melanocortin receptors throughout the brain and periphery. PT-141's multi-subtype agonism makes it a useful pharmacological tool for studying melanocortin system dynamics in research contexts where receptor subtype discrimination is not required. PT-141 is available from Lone Star Peptide Co. verified at ≥99% HPLC purity.

Melanocortin Receptor Subtypes, Pharmacological Profile

Receptor	Primary Expression	Research Relevance
MC1R	Melanocytes, immune cells	Pigmentation biology, immune modulation
MC2R	Adrenal cortex	ACTH-specific; PT-141 does not bind MC2R
MC3R	Hypothalamus, limbic system	Energy balance, feeding behavior research
MC4R	Hypothalamus, brainstem, spinal cord	Primary CNS target; energy homeostasis, reward
MC5R	Exocrine glands, peripheral tissues	Exocrine function, lipid metabolism research

MC4R Agonism and Hypothalamic Pathway Research

MC4R is expressed in multiple hypothalamic nuclei including the paraventricular nucleus (PVN) and arcuate nucleus, as well as in brainstem motor nuclei and spinal cord neurons. In hypothalamic cell models and slice preparations, MC4R agonism activates Gs-cAMP signaling and downstream regulation of neuropeptide expression, including suppression of AgRP (agouti-related protein), an endogenous inverse agonist at MC4R, and modulation of NPY/AgRP neuron activity.

For researchers studying energy homeostasis pathways, PT-141 provides a non-selective melanocortin agonist tool that can be used alongside subtype-selective compounds to dissect MC4R-specific versus MC3R-specific contributions to hypothalamic regulatory circuits. The compound's multi-receptor activity profile is well-documented, providing sufficient published data for designing appropriate controls in new research systems.

Receptor Subtype Selectivity Note

PT-141 is a non-selective melanocortin agonist. MC2R (ACTH receptor) is notably not activated, PT-141 does not stimulate cortisol release through MC2R in published studies, distinguishing it from ACTH and some other melanocortin peptides. For research designs requiring MC4R-specific effects, use of an MC4R-selective antagonist as a negative control (e.g., HS014) is recommended to confirm MC4R-specific pathway contributions.

Dopaminergic System Interactions

Published research documents interactions between the melanocortin system and mesolimbic dopaminergic pathways. In cell culture and rodent models, MC4R agonism modulates dopamine release in the nucleus accumbens and striatum, brain regions central to reward processing and motivated behavior research. This melanocortin-dopamine interface is an active area of CNS pharmacology research, with implications for studies examining neuromodulatory interactions between hypothalamic and mesolimbic circuits.

For researchers studying dopamine system pharmacology or reward circuit biology, PT-141's MC4R agonism provides a tool for examining melanocortin input to dopaminergic neurotransmission: a distinct mechanism from direct dopamine receptor agonists or reuptake inhibitors used in parallel experiments.

Storage and Laboratory Handling

PT-141 is a cyclic peptide supplied as a lyophilized white powder with good solubility in water and DMSO. Cyclic peptides generally have better conformational stability than linear peptides due to reduced backbone freedom, which contributes to PT-141's resistance to certain proteolytic enzymes. Store at −20°C, protected from light and moisture. Reconstituted solutions are stable at 4°C for up to 7 days. Verify identity and purity via your Certificate of Analysis before experimental use. See our peptide storage guide for handling protocols applicable to cyclic peptides.

Key Takeaways

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide with agonist activity at MC1R, MC3R, MC4R, and MC5R, but notably not MC2R (ACTH receptor).

MC4R agonism in hypothalamic models activates Gs-cAMP signaling and modulates neuropeptide expression including AgRP suppression in POMC circuit research.

Dopaminergic system interactions via melanocortin-dopamine circuit crosstalk are documented in mesolimbic pathway research.

Non-selective multi-subtype agonism requires use of subtype-selective antagonists as controls in research designs requiring receptor attribution.

Cyclic peptide structure confers improved conformational stability and proteolytic resistance compared to linear peptides of similar mass.

MC2R is not activated, PT-141 does not stimulate cortisol release, distinguishing its pharmacology from ACTH and some other melanocortin peptides.

Frequently Asked Questions

What is PT-141 and what receptors does it target?

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist. CAS 189691-06-3. It activates MC1R, MC3R, MC4R, and MC5R, with primary research interest at MC4R for hypothalamic and CNS pathway studies. It does not bind MC2R. For in vitro research use only.

What is MC4R and why is it important in research?

MC4R (melanocortin 4 receptor) is expressed in hypothalamic nuclei, brainstem, and spinal cord. It is a key regulator of energy homeostasis signaling, modulating neuropeptide expression (including AgRP) and interacting with mesolimbic dopaminergic circuits. MC4R agonism is studied extensively in energy balance and reward circuit research.

Does PT-141 affect cortisol levels through MC2R?

No. PT-141 does not bind MC2R (the ACTH receptor), which is the primary mechanism for HPA axis cortisol stimulation by melanocortin peptides. This distinguishes PT-141 from ACTH and some other melanocortin compounds in adrenal/cortisol research contexts.

How is PT-141 different from Melanotan II?

Melanotan II is a cyclic heptapeptide with a C-terminal amide. PT-141 (Bremelanotide) lacks this C-terminal amide, producing somewhat different receptor binding kinetics and pharmacological properties. Both are melanocortin receptor agonists, but PT-141 has a more selective CNS-focused pharmacological profile in published research.

How should PT-141 be stored?

Store lyophilized PT-141 at −20°C, protected from light and moisture. Reconstituted solutions are stable at 4°C for up to 7 days. The cyclic structure confers better conformational stability than linear peptides, but standard peptide storage protocols remain important for maintaining integrity.

FOR RESEARCH USE ONLY. All compounds referenced in this article are supplied exclusively for in vitro and laboratory research by qualified scientists. Not intended for human or animal consumption, therapeutic use, or clinical application. Lone Star Peptide Co. makes no therapeutic claims regarding any compound referenced herein.